Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma: A case report

Oncology

Volumn 66, Issue 2, 2004, Pages 160-163

  Meier, G ^a   Waldherr, C ^a   Herrmann, R ^a   Maecke, H ^a   Mueller Brand, J ^a   Pless, M ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

90Y DOTATOC; Merkel cell carcinoma; Neuroendocrine tumor; Skin neoplasms; Somatostatin

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; OCTAPEPTIDE; OCTREOTIDE; PEPTIDE DERIVATIVE; SOMATOSTATIN DERIVATIVE; YTTRIUM 90;

ABDOMINAL RADIOGRAPHY; AGED; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; CHEEK; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DOSE RESPONSE; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; KIDNEY FAILURE; LEUKOPENIA; MERKEL CELL TUMOR; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, MERKEL CELL; CHEEK; FACIAL NEOPLASMS; FATAL OUTCOME; FEMALE; HUMANS; OCTREOTIDE; RADIOPHARMACEUTICALS; SKIN NEOPLASMS; YTTRIUM RADIOISOTOPES;

EID: 2342489874     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077443     Document Type: Article

References (29)

1. Toker C: Trabecular carcinoma of the skin. Arch Dermatol 1972;105:107-110.
2. Schmidt U, Muller U, Metz KA, Leder LD: Cytokeratin and neurofilament protein staining in Merkel cell carcinoma of the small cell type and small cell carcinoma of the lung. Am J Dermatopathol 1998;20:346-351.
3. Hitchcock CL, Bland KI, Laney RG, Franzini D, Harris B, Copeland EM: Neuroendocrine (Merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment. Ann Surg 1988;207:201-207.
4. Gollard R, Weber R, Kosty MP, Greenway HAT, Massullo V, Humberson C: Merkel cell carcinoma: Review of 22 cases with surgical, pathologic, and therapeutic considerations. Cancer 2000;88:1842-1851.
5. Penn I, First MR: Merkel's cell carcinoma in organ recipients: Report of 41 cases. Transplantation 1999;68:1717-1721.
6. Brenner B, Sulkes A, Rakowsky E, Feinmesser M, Yukelson A, Bar-Haim E, Katz A, Idelevich E, Neuman A, Barhana M, Fenig E: Second neoplasms in patients with Merkel cell carcinoma. Cancer 2001;91:1358-1362.
7. Allen PJ, Zhang ZF, Coit DG: Surgical management of Merkel cell carcinoma. Ann Surg 1999;229:97-105.
8. Voog E, Biron P, Martin JP, Blay JY: Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 1999;85:2589-2595.
9. Ott MJ, Tanabe KK, Gadd MA, Stark P, Smith BL, Finkelstein DM, Souba WW: Multimodality management of Merkel cell carcinoma. Arch Surg 1999;134:388-393.
10. O'Connor WJ, Roenigk RK, Brodland DG: Merkel cell carcinoma. Comparison of Mohs micrographic surgery and wide excision in eighty-six patients. Dermatol Surg 1997;23:929-933.
11. Lawenda BD, Thiringer JK, Foss RD, Johnstone PA: Merkel cell carcinoma arising in the head and neck: Optimizing therapy. Am J Clin Oncol 2001;24:35-42.
12. Allen PJ, Busam K, Hill AD, Stojadinovic A, Coit DG: Immunohistochemical analysis of sentinel lymph nodes from patients with Merkel cell carcinoma. Cancer 2001;92:1650-1655.
13. Duker I, Starz H, Bachter D, Balda BR: Prognostic and therapeutic implications of sentinel lymphonodectomy and S-staging in Merkel cell carcinoma. Dermatology 2001;202:225-229.
14. Hill AD, Brady MS, Coit DG: Intraoperative lymphatic mapping and sentinel lymph node biopsy for Merkel cell carcinoma. Br J Surg 1999;86:518-521.
15. Linjawi A, Jamison WB, Meterissian S: Merkel cell carcinoma: Important aspects of diagnosis and management. Am Surg 2001;67:943-947.
16. Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, Bland KI, Beenken SW: Multimodality treatment of Merkel cell carcinoma: Case series and literature review of 1,024 cases. Ann Surg Oncol 2001;8:204-208.
17. Kokoska ER, Kokoska MS, Collins BT, Stapleton DR, Wade TP: Early aggressive treatment for Merkel cell carcinoma improves outcome. Am J Surg 1997;174:688-693.
18. Savage P, Constenla D, Fisher C, Thomas JM, Gore ME: The natural history and management of Merkel cell carcinoma of the skin: A review of 22 patients treated at the Royal Marsden Hospital. Clin Oncol (R Coll Radiol) 1997;9:164-167.
19. Fenig E, Brenner B, Katz A, Rakovsky E, Hana MB, Sulkes A: The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. Cancer 1997;80:881-885.
20. Wilder RB, Harari PM, Graham AR, Shimm DS, Cassady JR: Merkel cell carcinoma. Improved locoregional control with postoperative radiation therapy. Cancer 1991;68:1004-1008.
21. Gillenwater AM, Hessel AC, Morrison WH, Burgess M, Silva EG, Roberts D, Goepfert H: Merkel cell carcinoma of the head and neck: Effect of surgical excision and radiation on recurrence and survival. Arch Otolaryngol Head Neck Surg 2001;127:149-154.
22. Tai PT, Yu E, Winquist E, Hammond A, Stitt L, Tonita J, Gilchrist J: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: Case series and review of 204 cases. J Clin Oncol 2000;18:2493-2499.
23. Guitera-Rovel P, Lumbroso J, Gautier-Gougis MS, Spatz A, Mercier S, Margulis S, Mamelle G, Kolb F, Lartigau E, Avril MF: Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases. Ann Oncol 2001;12:807-811.
24. Maecke HR, Béhé M, Froidevaux S: DOTAD-Phe(1)-Tyr(3)- octreotide (DOTATOC): A unique somatostatin receptor ligand for labeling with a variety of metallic radionuclides. J Nucl Med 1997;38:18P.
25. Béhé M, Heppeler A, Maecke HR: New somatostatin analogs for SPET and PET (abstract). Eur J Nucl Med 1996;23:1144.
26. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR: Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417-418.
27. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J: Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999;26:1439-1447.
28. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 2001;12:941-945.
29. 3-octreotide: A pilot study. Nucl Med Commun 2001;22:673-678.